2BBBullish & Bearish
Pluri Inc. (PLUR) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 21 out of 100.
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
Pluri Inc.’s current 2BB score is 21 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 0 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 3 | Very Weak |
| Quality | 100 | Very Strong |
| Risk | 58 | Moderate |
| CEO | Yaky Yanay |
| Headquarters | Haifa, Haifa District, Israel |
| Founded | May 11, 2001 |
| Employees | 135 |
| 52-week range | $1.45 – $5.68 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-10 | — | — | — | — |
| 2026-11-10 | — | — | — | — |
| 2026-09-15 | — | -0.6732 | — | $668,100.00 |
| 2026-05-11 | — | -0.6732 | — | $668,100.00 |